Short Interest in Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) Decreases By 78.8%

Sigyn Therapeutics, Inc. (OTCMKTS:SIGY) was the target of a significant decline in short interest during the month of July. As of July 15th, there was short interest totaling 1,501 shares, a decline of 78.8% from the June 30th total of 7,095 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 118,747 shares, the short-interest ratio is currently 0.0 days.

Sigyn Therapeutics Stock Performance

OTCMKTS SIGY opened at $0.03 on Monday. The firm has a market capitalization of $75,946.00, a P/E ratio of -0.01 and a beta of -0.08. The firm’s fifty day moving average price is $0.04 and its two-hundred day moving average price is $0.22. Sigyn Therapeutics has a 1 year low of $0.01 and a 1 year high of $5.00.

Sigyn Therapeutics (OTCMKTS:SIGY) last announced its quarterly earnings data on Thursday, July 16th. The company reported ($0.42) EPS for the quarter.

Sigyn Therapeutics Company Profile

Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.